NCT03711890
Ultra-High Resolution Optical Coherence Tomography in Detecting Micrometer Sized Early Stage Pancreatic Cancer in Participants With Pancreatic Cancer
Recruiting
NAAges 18+InterventionalDiagnosticOhio State University Comprehensive Cancer CenterInvestigator-initiated
~75 participants
Updated 2026-06-15 on ClinicalTrials.gov
What's tested:Optical Coherence TomographyTherapeutic Conventional SurgeryLaboratory Evaluation
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Measure accuracy of using OCT to diagnose pancreatic cancer and compare with histology.
Measured over Up to 3 years
Conditions
Where it's being run
1 sites across 1 statesOhio1
Study leadership
- Mary Dillhoff, MD · PRINCIPAL_INVESTIGATOR · Ohio State University Comprehensive Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Immediate surgery cohort: Adult patients with pancreatic cancer or IPMN
Immediate surgery cohort: Informed consent will be obtained
Adult patients undergoing pancreatic resection for a presumed IPMN
Exclusion
Pregnant
What this trial measures
- Measure accuracy of using OCT to diagnose pancreatic cancer and compare with histology.Up to 3 years
Will evaluate the accuracy of the optical coherence tomography (OCT) based diagnosis compare to the pathological diagnosis or the cancer cell derived exosomes test from the blood sample. Will compare the diagnosis results from the OCT imaging technology to standard histopathologic assessment and the blood test using 2-way tables. The agreement between two tests will be summarized with the overall agreement and the Cohen?s Kappa values.